Abstract
Since 1972 the Treatment Subgroup of the National Prostatic Cancer Project has accessioned 1748 patients with various stages of prostatic cancer to 13 different treatment protocols. Seven of these protocols have been closed and the results in the initial studies have been published. Six protocols are active and continue to accrue patients. Principal investigators have a prominent role in protocol design as well as in the evaluation and publication of data emanating from these protocols. Active agents identified to date include cyclophosphamide, 5-fluorouracil, methyl-CCNU, imidazole-carboxamide, estramustine phosphate and streptozotocin. Agents chosen for their presumed activity, but currently under investigation, include methotrexate and cis-platinum.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
W.W. Scott, R.P. Gibbons, D.E. Johnson, G.R. Prout, Jr., J.D. Schmidt, J. Saroff, and G.P. Murphy, The continued evaluation of the effects of chemotherapy in patients with advanced carcinoma of the prostate, J. Urol. 116:211 (1976).
G.P. Murphy, R.P. Gibbons, D.E. Johnson, S.A. Loening, G.R. Prout, J.D. Schmidt, D.S. Bross, T.M. Chu, J.F. Gaeta, J. Saroff, and W.W. Scott, A comparison of estramustine phosphate and streptozotocin in patients with advanced prostatic carcinoma who have had extensive irradiation, J. Urol 118:288 (1977).
J.D. Schmidt, W.W. Scott, R.P. Gibbons, D.E. Johnson, G.R. Prout, Jr., S.A. Loening, M.S. Soloway, T.M. Chu, J.F. Gaeta, N.H. Slack, J. Saroff, and G.P. Murphy, Comparison of procarbazine, imidazole-carboxamide and cyclophosphamide in relapsing patients with advanced carcinoma of the prostate, J. Urol. 121:185 (1979).
S.A. Loening, J.B. deKernion, R.P. Gibbons, D.E. Johnson, J.E. Pontes, G.R. Prout, Jr., J.D. Schmidt, W.W. Scott, M.S. Soloway, N.H. Slack, and G.P. Murphy, A comparison of hydroxyurea, methyl-CCNU and cyclophosphamide in patients with advanced carcinoma of the prostate, J. Urol. In Press.
G.P. Murphy, R.P. Gibbons, D.E. Johnson, G.R. Prout, J.D. Schmidt, M.S. Soloway, S.A. Loening, T.M Chu, J.F. Gaeta, J. Saroff, Z. Wajsman, N. Slack, and W.W. Scott, The use of estramustine and prednimustine versus prednimustine alone in advanced metastatic prostatic cancer patients who have received prior irradiation, J. Urol, 121:763 (1979).
M.S. Soloway, J.B. deKernion, R.P. Gibbons, D.E. Johnson, S. Loening, J.E. Pontes, G.R. Prout, J.D. Schmidt, W.W. Scott, N.H. Slack, and G.P. Murphy, Comparison of Estracyt and vincristine alone or in combination for patients with advanced hormone-refractory, previously irradiated carcinoma of the prostate, J. Urol. In Press.
J.D. Schmidt, W.W. Scott, R. Gibbons, D.E. Johnson, G.R. Prout, Jr., S. Loening. M. Soloway, J. deKernion, J.E. Pontes, N.H. Slack, and G.P. Murphy, Chemotherapy programs of the National Prostatic Cancer project, Cancer 45:1937 (1980).
R.P. Gibbons and Investigators, National Prostatic Cancer Project Cooperative Clinical Trials: Cooperative clinical trial of single and combined agent protocols: Adjuvant protocols, Urology (Suppl.), 17:48 (1981).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1983 Springer Science+Business Media New York
About this chapter
Cite this chapter
Schmidt, J.D. (1983). Chemotherapy of Prostate Cancer: The National Prostatic Cancer Project Experience. In: Pavone-Macaluso, M., Smith, P.H. (eds) Cancer of the Prostate and Kidney. NATO Advanced Science Institutes Series, vol 53. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-4349-3_47
Download citation
DOI: https://doi.org/10.1007/978-1-4684-4349-3_47
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-4351-6
Online ISBN: 978-1-4684-4349-3
eBook Packages: Springer Book Archive